IHC- and FCM-validated Antibodies for SARS-CoV-2 Research

As researchers and clinicians learn more about SARS-CoV-2 and COVID-19, their newfound knowledge leads to new questions. This relentless process demands that their research tools evolve to maintain the momentum necessary to spur further discovery.

GeneTex’s SARS-CoV-2 antibody catalog is expanding both in product number and in validated applications. Multiple publications document the utility of one of its mouse monoclonal Spike (S2) antibodies (GTX632604) for immunohistochemistry, which is of crucial significance as scientists work to identify the mechanisms underlying the effects of the virus on different tissues and organ systems (1, 2, 3, 4). Similarly, an exciting study in the New England Journal of Medicine cited one of GeneTex’s SARS-CoV-2 Nucleocapsid antibodies (GTX135357) for IHC in its analysis of one of the most promising vaccine candidates (5). In addition, preliminary evidence from a collaborating academic lab demonstrates the successful use of two GeneTex antibodies for flow cytometry of SARS-CoV-2-infected cells (i.e., GTX632696 and GTX135357). These findings add new applications to products already shown to perform for western blot, immunocytochemistry, and ELISA.

The GeneTex team remains committed to bringing researchers thoroughly validated reagents to accelerate their efforts against the SARS-CoV-2/COVID-19 pandemic. For more information, please go to www.genetex.com or contact us directly.

Highlighted Products

SARS-CoV / SARS-CoV-2 (COVID-19) Spike antibody [1A9] (GTX632604)

SARS-CoV / SARS-CoV-2 (COVID-19) Spike antibody [1A9] (GTX632604)

SARS-CoV-2 (COVID-19) Nucleocapsid antibody (GTX135357)

SARS-CoV / SARS-CoV-2 (COVID-19) NSP8 antibody [5A10] (GTX632696)

References:

1. Br J Dermatol. 2020 Jun 20;10.1111/bjd.19327.
2. Mod Pathol. 2020 Jul 3;1-8.
3. Br J Dermatol. 2020 Jun 25;10.1111/bjd.19338.
4. Eur J Clin Microbiol Infect Dis. 2020 Jul 13;1-5.
5. N Engl J Med. 2020 Jul 28.